Show simple item record

An open-label extension study to evaluate safety and efficacy of Pazopanib in patients with advanced renal cell carcinoma.

dc.contributor.authorSternberg, C
dc.contributor.authorDavis, I
dc.contributor.authorDeen, K
dc.contributor.authorSigal, E
dc.contributor.authorHawkins, Robert E
dc.date.accessioned2015-01-26T11:12:22Z
dc.date.available2015-01-26T11:12:22Z
dc.date.issued2014
dc.identifier.citationAn open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. 2014, 87 (6):342-50 Oncologyen
dc.identifier.issn1423-0232
dc.identifier.pmid25227656
dc.identifier.doi10.1159/000366227
dc.identifier.urihttp://hdl.handle.net/10541/338852
dc.description.abstractEvaluation of the safety and efficacy of pazopanib, a multikinase angiogenesis inhibitor, in a single-arm, open-label, extension study (VEG107769/NCT00387764) for placebo-treated patients with advanced renal cell carcinoma (RCC) from a randomized, double-blind, placebo-controlled phase III study (VEG105192/NCT00334282).
dc.language.isoenen
dc.rightsArchived with thanks to Oncologyen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAnorexia
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshDiarrhea
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshHair Color
dc.subject.meshHumans
dc.subject.meshHypertension
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshKidney Neoplasms
dc.subject.meshLymphatic Metastasis
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNausea
dc.subject.meshNeoplasm Staging
dc.subject.meshPyrimidines
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshSeverity of Illness Index
dc.subject.meshSulfonamides
dc.subject.meshTreatment Outcome
dc.titleAn open-label extension study to evaluate safety and efficacy of Pazopanib in patients with advanced renal cell carcinoma.en
dc.typeArticleen
dc.contributor.department1Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italyen
dc.identifier.journalOncologyen
html.description.abstractEvaluation of the safety and efficacy of pazopanib, a multikinase angiogenesis inhibitor, in a single-arm, open-label, extension study (VEG107769/NCT00387764) for placebo-treated patients with advanced renal cell carcinoma (RCC) from a randomized, double-blind, placebo-controlled phase III study (VEG105192/NCT00334282).


This item appears in the following Collection(s)

Show simple item record